Latest news with #NCCNClinicalPracticeGuidelinesinOncology
Business Wire
25-06-2025
- Health
- Business Wire
Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program ® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. The study, 'Validation of a Digital Tool that Uses National Testing Guidelines to Identify Individuals at Risk for Hereditary Cancer,' demonstrated that the CARE program accurately interprets NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 1,2 with 99.5% accuracy, reinforcing its effectiveness as a digital risk assessment tool for identifying patients who may benefit from hereditary cancer-focused genetic testing and personalized care. Approximately 5% of individuals have a mutation in a cancer predisposition gene, yet most are unaware. 3 NCCN Guidelines® are a trusted source for hereditary cancer testing criteria, but their complexity and frequent updates may make them difficult for non-specialist clinicians and digital health tools to apply effectively. CARE addresses this gap by streamlining the hereditary cancer risk assessment process. 'The validation of CARE's accuracy reinforces what we've experienced at HCA Healthcare's Sarah Cannon Cancer Network – that, in addition to being well received by our patients, CARE's assessment can reliably identify patients who need genetic services,' said Dr. Dax Kurbegov, Vice President and Physician-In-Chief of Clinical Programs, HCA Healthcare's Sarah Cannon Cancer Network. 'With demonstrated 99.5% accuracy in applying clinical guidelines, we can confidently scale hereditary cancer risk assessment across our community hospitals, ensuring more patients have access to potentially life-saving genetic insights.' The Ambry CARE Program® leverages digital health solutions to enable health systems to stratify patients by cancer risks, driving personalized, proactive care. Its HIPAA-compliant application integrates with electronic health records and collects medical and family history directly from patients via a mobile-friendly assessment prior to in-person visits. The program weighs these data against guidelines to identify those who qualify for hereditary cancer testing and/or increased breast cancer screening based on estimated breast cancer risk. This enables clinicians to make timely, evidenced-based medical decisions, while offering patients education and connection to third-party genetic counseling at no additional cost. The newly published study assessed CARE's accuracy by using the program to identify cases that met hereditary cancer testing criteria based on NCCN Guidelines for hereditary breast, ovarian, pancreatic, and prostate cancer, as well as for Lynch syndrome and familial adenomatous polyposis 1,2. Researchers then compared CARE's results against those of certified genetic counselors reviewing the same cases, confirming its ability to accurately identify 398 out of 400 real-world patient cases. 'CARE offers healthcare systems a quality, end-to-end solution that transforms how they identify the need for, implement, and scale genetic testing,' added Tom Schoenherr, CEO of Ambry Genetics. 'Because clinicians can trust CARE's comprehensive history collection and accurate risk assessment, they can feel confident expanding access to genetic services, improving outcomes for more patients, and making genetic testing a seamless part of their patient care and population health strategies.' NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V2.2025. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed February 6, 2025. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V3.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed February 6, 2025. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW. Cascade genetic testing of relatives for hereditary cancer risk: results of an online initiative. J Natl Cancer Inst. 2019;111(1):95-98. doi:10.1093/jnci/djy147 ABOUT AMBRY GENETICS® Ambry Genetics translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Its unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners, means Ambry Genetics is first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. ABOUT TEMPUS Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Ambry Genetic's research and publications; the contributions of Ambry Genetic's research and findings to the larger scientific community and the use of its products and services to advance clinical care for patients are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Yahoo
24-06-2025
- Health
- Yahoo
Trusted Oncology Guidelines Get a Digital Makeover: National Comprehensive Cancer Network Launches NCCN Guidelines Navigator
The new interactive guideline tool represents a major format change for gold-standard NCCN Guidelines. PLYMOUTH MEETING, Pa., June 24, 2025 /CNW/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines® are the recognized standard for clinical decision making and policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. They assist in the decision-making process of individuals involved in cancer care and prevention—including physicians, nurses, pharmacists, payers, patients and their caregivers—with the ultimate goal of improving patient care and outcomes. The new NCCN Guidelines Navigator™ presents the evidence-based, expert consensus-driven recommendations from the NCCN Guidelines in a virtual platform that allows users to search and navigate more easily. Access to the NCCN Guidelines Navigator™ is available with a free NCCN account for non-commercial use. Features of the NCCN Guidelines Navigator™ include: Seamless movement throughout a guideline using table of contents or search features Advanced search capabilities and the ability to use filters Highlighter feature for relevant content pathways Color-coded navigation links Easily viewed footnotes linked directly from the pathways Direct links to NCCN Guidelines for Patients® Direct links to the relevant NCCN Chemotherapy Order Templates (NCCN Templates®) for subscribers Zoom capabilities Mobile friendly Built-in tutorial and frequently asked questions Links to PDF format of the guideline "This is truly the future of cancer treatment guidance," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "Cancer prevention, screening, treatment, and supportive care that follows internationally-trusted guidelines has been shown time and again to improve outcomes for people with cancer. I'm proud that we've achieved our ambitious goal for increasing the accessibility and usability of the content from the NCCN Guidelines without compromising any quality." The NCCN Guidelines Navigator™ recently began beta testing for colon and prostate cancers. That was followed by rectal cancer, which was published on June 16, 2025. NCCN will continue to publish NCCN Guidelines Navigator™ for additional cancer types until all 88 NCCN Guidelines are available in the new format. The original pdf format will also remain available for all NCCN Guidelines. Both forms will feature the most up-to-date information users rely upon for daily use in cancer care and prevention. People who access the NCCN Guidelines in any format, including via the NCCN Guidelines Navigator™, can earn CE/MOC credit through the new NCCN Guidelines in Practice™—which was just announced earlier this month. NCCN also plans to continue to optimize this new tool, including adding artificial intelligence (AI) capabilities to make searching even more conversational and intuitive, plus increased integration with NCCN's other resource offerings. "It has been 30 years since we first launched the NCCN Guidelines; since then, they have come to be used by millions of people worldwide every year, including more than 90% of U.S. and global physicians surveyed," said Dr. Denlinger. "Cancer care is becoming increasingly effective but also more complicated every year. The new NCCN Guidelines Navigator tool simplifies the evolving evidence from the latest research, leverages expertise to put it into context, and places it at the point-of-care for decision-making support and education. This new resource integrates everything we do to support people with cancer and their care providers by defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives." Visit for more information. About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit for more information. Media Contact:Rachel Darwin267-622-6624darwin@ View original content to download multimedia: SOURCE National Comprehensive Cancer Network View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Health
- Yahoo
New Continuing Education Tool from NCCN Enables Care Providers to Earn Credits While Supporting Cancer Patients
The NCCN Guidelines in Practice™ helps busy health care professionals earn credits toward maintaining licensure and board certification while applying immediate, evidence-based updates to their practice. PLYMOUTH MEETING, Pa., June 16, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has launched a new continuing education (CE) resource: NCCN Guidelines in Practice™. This new subscription service equips health professionals with continuing education tools to support care decision-making and delivery according to the latest evidence-based, expert consensus-driven recommendations, while earning continuing education and Maintenance of Certification (MOC) credits for the NCCN Guidelines engagement they are already doing during their daily clinical work. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are the recognized standard for clinical direction and policy in cancer care in the United States. They are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. The 88 different NCCN Guidelines® cover treatment for nearly every type of cancer, plus prevention, screening, supportive care, and related topics. Numerous independent studies have shown that guideline-concordant care is correlated with better outcomes, longer survival, and lower costs. Individuals who subscribe to the NCCN Guidelines in Practice™ will be able to track every time they utilize one of the NCCN Guidelines while determining the best course of action for their patients—an activity that occurred more than 16 million times in 2024—and seamlessly receive continuing education credit toward maintaining their licensure and board certification. NCCN Guidelines in Practice is approved for AMA PRA Category 1 Credit™ for physicians and awards contact hours for physician associates, nurse practitioners, and nurses. Other members of the oncology care team can receive a certificate of participation. "As a board-certified, practicing oncologist myself, it's hard to express just how exciting this is," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "The NCCN Guidelines in Practice put education where we need it most—at the point-of-care. This will help busy clinicians stay current on cutting-edge cancer care, particularly for some of the rarer cancer types that are covered by the NCCN Guidelines but less likely to be addressed by an in-person or online course. What's more, learning and credit for this continuing education exercise is immediate. As soon as a guideline update is published, people can earn continuing education credit for accessing the latest information." For those who prefer more in-depth explanations for updated treatment recommendations, plus a look at the underlying research and the opportunity to ask questions directly to the experts—NCCN hosts an Annual Conference, Annual Hematologic Malignancies Congress, Breast Cancer Congress, and other events and webinars. These events include in-person networking opportunities, along with virtual and on-demand access to CE content as well. "We recognize that there are providers who specialize in other areas of medicine who use the NCCN Guidelines to learn about oncology updates as well, such as primary care physicians or pediatricians," said Kristin Kline Hasson, Senior Director of Continuing Education, NCCN. "The NCCN Guidelines in Practice makes it easy for everyone to access the information they need while maintaining their required certifications, without adding to an already heavy workload." NCCN Guidelines in Practice is designed for simplicity and ease-of-use, built right into the NCCN website with no separate log-ins. The subscription service seamlessly tracks guideline usage, provides certificates of completion, and, in many cases, automatically syncs with the relevant state medical and certification boards. Visit for more information, including a list of frequently asked questions, and to purchase a subscription. About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit for more information. Media Contact: Rachel Darwin267-622-6624darwin@ View original content to download multimedia: SOURCE National Comprehensive Cancer Network Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Health
- Yahoo
Trusted Oncology Guidelines Get a Digital Makeover: National Comprehensive Cancer Network Launches NCCN Guidelines Navigator
The new interactive guideline tool represents a major format change for gold-standard NCCN Guidelines. PLYMOUTH MEETING, Pa., June 24, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines® are the recognized standard for clinical decision making and policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. They assist in the decision-making process of individuals involved in cancer care and prevention—including physicians, nurses, pharmacists, payers, patients and their caregivers—with the ultimate goal of improving patient care and outcomes. The new NCCN Guidelines Navigator™ presents the evidence-based, expert consensus-driven recommendations from the NCCN Guidelines in a virtual platform that allows users to search and navigate more easily. Access to the NCCN Guidelines Navigator™ is available with a free NCCN account for non-commercial use. Features of the NCCN Guidelines Navigator™ include: Seamless movement throughout a guideline using table of contents or search features Advanced search capabilities and the ability to use filters Highlighter feature for relevant content pathways Color-coded navigation links Easily viewed footnotes linked directly from the pathways Direct links to NCCN Guidelines for Patients® Direct links to the relevant NCCN Chemotherapy Order Templates (NCCN Templates®) for subscribers Zoom capabilities Mobile friendly Built-in tutorial and frequently asked questions Links to PDF format of the guideline "This is truly the future of cancer treatment guidance," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "Cancer prevention, screening, treatment, and supportive care that follows internationally-trusted guidelines has been shown time and again to improve outcomes for people with cancer. I'm proud that we've achieved our ambitious goal for increasing the accessibility and usability of the content from the NCCN Guidelines without compromising any quality." The NCCN Guidelines Navigator™ recently began beta testing for colon and prostate cancers. That was followed by rectal cancer, which was published on June 16, 2025. NCCN will continue to publish NCCN Guidelines Navigator™ for additional cancer types until all 88 NCCN Guidelines are available in the new format. The original pdf format will also remain available for all NCCN Guidelines. Both forms will feature the most up-to-date information users rely upon for daily use in cancer care and prevention. People who access the NCCN Guidelines in any format, including via the NCCN Guidelines Navigator™, can earn CE/MOC credit through the new NCCN Guidelines in Practice™—which was just announced earlier this month. NCCN also plans to continue to optimize this new tool, including adding artificial intelligence (AI) capabilities to make searching even more conversational and intuitive, plus increased integration with NCCN's other resource offerings. "It has been 30 years since we first launched the NCCN Guidelines; since then, they have come to be used by millions of people worldwide every year, including more than 90% of U.S. and global physicians surveyed," said Dr. Denlinger. "Cancer care is becoming increasingly effective but also more complicated every year. The new NCCN Guidelines Navigator tool simplifies the evolving evidence from the latest research, leverages expertise to put it into context, and places it at the point-of-care for decision-making support and education. This new resource integrates everything we do to support people with cancer and their care providers by defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives." Visit for more information. About the National Comprehensive Cancer NetworkThe National Comprehensive Cancer Network® (NCCN®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit for more information. Media Contact:Rachel Darwin267-622-6624darwin@ View original content: SOURCE National Comprehensive Cancer Network Sign in to access your portfolio
Korea Herald
24-06-2025
- Health
- Korea Herald
Trusted Oncology Guidelines Get a Digital Makeover: National Comprehensive Cancer Network Launches NCCN Guidelines Navigator
The new interactive guideline tool represents a major format change for gold-standard NCCN Guidelines. PLYMOUTH MEETING, Pa., June 24, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network ® (NCCN ®)—an alliance of leading cancer centers—announces a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®). The NCCN Guidelines ® are the recognized standard for clinical decision making and policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine. They assist in the decision-making process of individuals involved in cancer care and prevention—including physicians, nurses, pharmacists, payers, patients and their caregivers—with the ultimate goal of improving patient care and outcomes. The new NCCN Guidelines Navigator ™ presents the evidence-based, expert consensus-driven recommendations from the NCCN Guidelines in a virtual platform that allows users to search and navigate more easily. Access to the NCCN Guidelines Navigator™ is available with a free NCCN account for non-commercial use. Features of the NCCN Guidelines Navigator™ include: "This is truly the future of cancer treatment guidance," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "Cancer prevention, screening, treatment, and supportive care that follows internationally-trusted guidelines has been shown time and again to improve outcomes for people with cancer. I'm proud that we've achieved our ambitious goal for increasing the accessibility and usability of the content from the NCCN Guidelines without compromising any quality." The NCCN Guidelines Navigator™ recently began beta testing for colon and prostate cancers. That was followed by rectal cancer, which was published on June 16, 2025. NCCN will continue to publish NCCN Guidelines Navigator™ for additional cancer types until all 88 NCCN Guidelines are available in the new format. The original pdf format will also remain available for all NCCN Guidelines. Both forms will feature the most up-to-date information users rely upon for daily use in cancer care and prevention. People who access the NCCN Guidelines in any format, including via the NCCN Guidelines Navigator™, can earn CE/MOC credit through the new NCCN Guidelines in Practice ™—which was just announced earlier this month. NCCN also plans to continue to optimize this new tool, including adding artificial intelligence (AI) capabilities to make searching even more conversational and intuitive, plus increased integration with NCCN's other resource offerings. "It has been 30 years since we first launched the NCCN Guidelines; since then, they have come to be used by millions of people worldwide every year, including more than 90% of U.S. and global physicians surveyed," said Dr. Denlinger. "Cancer care is becoming increasingly effective but also more complicated every year. The new NCCN Guidelines Navigator tool simplifies the evolving evidence from the latest research, leverages expertise to put it into context, and places it at the point-of-care for decision-making support and education. This new resource integrates everything we do to support people with cancer and their care providers by defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives." Visit for more information. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network ® (NCCN ®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients ® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation ®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit for more information.
